Brief: Cabaletta Bio Inc Reports New Data From RESET-PV Trial
09/10/2025 17:23
Oct 9 (Reuters) - Cabaletta Bio Inc CABA.O: CABALETTA BIO INC - REPORTS NEW DATA FROM RESET-PV TRIAL - SEC FILING CABALETTA BIO INC - RESE-CEL WELL TOLERATED WITH NO ICANS REPORTED - SEC FILING CABALETTA BIO INC - ALL THREE PATIENTS EXPERIENCED SUBSTANTIAL DEPLETION OF B CELLS WITHIN THE FIRST MONTH POST-INFUSION CABALETTA BIO INC - PATIENTS 2 AND 3 ACHIEVED COMPLETE PERIPHERAL B CELL DEPLETION Source text: [ID:n0001193125-25-235533] Further company coverage: CABA.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview